BiotechTube

BNT162b2

ApprovedCompleted
0 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

SARS-CoV-2 Infection

Conditions

SARS-CoV-2 Infection, COVID-19

Trial Timeline

Oct 21, 2020 → Nov 25, 2021

NCT ID
NCT04588480

About BNT162b2

BNT162b2 is a approved stage product being developed by Pfizer for SARS-CoV-2 Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT04588480. Target conditions include SARS-CoV-2 Infection, COVID-19.

What happened to similar drugs?

3 of 20 similar drugs in SARS-CoV-2 Infection were approved

Approved (3) Terminated (1) Active (17)
✅mRNA-1273 Variant-containing FormulationModernaApproved
✅mRNA-1273ModernaApproved
✅AZD1222AstraZenecaApproved
🔄mRNA-1273ModernaPhase 3
🔄mRNA-1273ModernaPhase 3
🔄mRNA-1083ModernaPhase 3
🔄mRNA-1273ModernaPhase 3

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (8)

NCT IDPhaseStatus
NCT06923137Pre-clinicalActive
NCT05621239Pre-clinicalCompleted
NCT04895982Phase 2Completed
NCT04880447Pre-clinicalCompleted
NCT04816669Phase 3Completed
NCT04815031Pre-clinicalCompleted
NCT04754594Phase 2/3Completed
NCT04588480ApprovedCompleted

Competing Products

20 competing products in SARS-CoV-2 Infection

See all competitors
ProductCompanyStageHype Score
mRNA-1010ModernaPhase 1
0
mRNA-1273ModernaPreclinical
0
mRNA-1273ModernaPhase 1
0
mRNA-1283ModernaPhase 1
0
mRNA-1273ModernaPreclinical
0
mRNA-1083 Composition 1 Dose A Lot AModernaPhase 2
0
mRNA-1273.214ModernaPhase 2
0
SPIKEVAXModernaPreclinical
0
mRNA-1273ModernaPhase 3
0
mRNA-1273ModernaPhase 3
0
mRNA-1273ModernaPreclinical
0
mRNA-1083.1ModernaPhase 2
0
SPIKEVAX BivalentModernaPreclinical
0
mRNA-1083ModernaPhase 3
0
mRNA-1273ModernaPhase 2
0
mRNA-1073ModernaPhase 2
0
mRNA-1273ModernaPhase 3
0
mRNA-1273ModernaPreclinical
0
mRNA-1273.211ModernaPhase 3
0
SPIKEVAX (mRNA-1273)ModernaPreclinical
0